1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. WuXi Biologics (Cayman) Inc.
  6. Summary
    2269   KYG970081173

WUXI BIOLOGICS (CAYMAN) INC.

(2269)
  Report
Delayed Hong Kong Stock Exchange  -  05/26 11:29:38 pm EDT
54.65 HKD   +7.90%
05/20Correction to Vir Biotechnology Shares Fall 9% Article
DJ
05/20Vir Biotechnology Shares Fall 9% After Terminating Agreement with WuXi Bio
DJ
05/20China stocks rise on higher-than-expected borrowing rate cut; foreign inflows surge
RE
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Hong Kong Stock Exchange
05/20/2022 05/23/2022 05/24/2022 05/25/2022 05/26/2022 Date
56.3(c) 56.25(c) 53.1(c) 53.3(c) 50.65(c) Last
23 894 610 17 402 362 18 220 959 9 610 267 21 827 266 Volume
+7.85% -0.09% -5.60% +0.38% -4.97% Change
More quotes
Estimated financial data (e)
Sales 2022 14 998 M 2 241 M 2 241 M
Net income 2022 4 575 M 684 M 684 M
Net cash position 2022 6 536 M 977 M 977 M
P/E ratio 2022 42,2x
Yield 2022 -
Sales 2023 20 659 M 3 087 M 3 087 M
Net income 2023 6 316 M 944 M 944 M
Net cash position 2023 8 759 M 1 309 M 1 309 M
P/E ratio 2023 30,7x
Yield 2023 -
Capitalization 192 B 28 644 M 28 644 M
EV / Sales 2022 12,3x
EV / Sales 2023 8,85x
Nbr of Employees 9 864
Free-Float 84,2%
More Financials
Company
WUXI BIOLOGICS (CAYMAN) INC. is an investment holding company. The Company along with its subsidiaries is mainly engaged in the discovery, research and development, manufacturing and sales of biologics products. The Company’s primary products include the clinical active pharmaceutical ingredients, sterile liquid preparations, freeze-dried preparations, as well as small molecules antibiotics for injection drugs.... 
Sector
Pharmaceuticals
Calendar
08/22Earnings Release
More about the company
Ratings of WuXi Biologics (Cayman) Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about WUXI BIOLOGICS (CAYMAN) INC.
05/20Correction to Vir Biotechnology Shares Fall 9% Article
DJ
05/20Vir Biotechnology Shares Fall 9% After Terminating Agreement with WuXi Bio
DJ
05/20China stocks rise on higher-than-expected borrowing rate cut; foreign inflows surge
RE
05/11Hong Kong Stocks Rebound from Near Two-Month Low; Biotech Shares Rally
MT
04/27WuXi Biologics' 2021 ESG Report Reveals Company's Strong Commitment to Overall Sustaina..
PR
04/27WUXI BIOLOGICS CAYMAN : 2021 ESG Report
PU
04/14WUXI BIOLOGICS CAYMAN : Receives Bioprocessing Excellence Award from IMAPAC
PU
03/29UBS Adjusts Wuxi Biologics' Price Target to HK$110.67 From HK$142, Keeps at Buy
MT
03/24Nomura Adjusts WuXi Biologics' Price Target to HK$100.87 From HK$103.28, Keeps at Buy
MT
03/23Hong Kong Stocks Stage Back-to-Back Gains; Xiaomi, WuXi Bio Shares Jump on Upbeat Earni..
MT
03/23WUXI BIOLOGICS CAYMAN : 2021 Annual Results (in PDF)
PU
03/23China shares end higher on stimulus hopes as COVID cases rise
RE
03/23China shares end higher on stimulus hopes as COVID cases rise
RE
03/23China shares subdued as investors eye stimulus amid higher COVID cases
RE
03/22WUXI BIOLOGICS CAYMAN : Achieved Record Growth and Profitability in 2021 Banner Year for C..
PU
More news
News in other languages on WUXI BIOLOGICS (CAYMAN) INC.
05/11Les actions de Hong Kong se redressent après avoir atteint leur plus bas niveau depuis ..
05/09Création d'un SPAC dédié à la fabrication des produits biopharmaceutiques à Paris
05/09Création d'un SPAC dédié à la fabrication des produits biopharmaceutiques à Paris
05/09Se crea la primera SPAC europea centrada en la producción de medicamentos complejos
03/23Les actions de Hong Kong enregistrent deux gains consécutifs ; les actions de Xiaomi et..
More news
Analyst Recommendations on WUXI BIOLOGICS (CAYMAN) INC.
More recommendations
Chart WUXI BIOLOGICS (CAYMAN) INC.
Duration : Period :
WuXi Biologics (Cayman) Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends WUXI BIOLOGICS (CAYMAN) INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 26
Last Close Price 45,44 CNY
Average target price 92,50 CNY
Spread / Average Target 104%
EPS Revisions
Managers and Directors
Zhi Sheng Chen Director
Ming Tu Chief Financial Officer & Executive Vice President
Ge Li Non-Executive Chairman
Weichang Zhou Chief Technology Officer & Executive Director
William Robert Keller Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
WUXI BIOLOGICS (CAYMAN) INC.-42.41%28 644
CSL LIMITED-5.89%93 252
SAMSUNG BIOLOGICS CO.,LTD.-7.97%46 658
BIOGEN INC.-15.66%29 636
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-28.05%21 435
UCB-17.63%16 697